| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
School of Medicine, University of New South Wales, Sydney, New South Wales, Australia;
Department of Medical Oncology, St. Vincent’s Hospital, Darlinghurst, New South Wales, Australia; and
Universitat Heidelberg, Molekulare Genetik, Heidelberg, Germany
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A number of anti-ErbB-2 ECD mAbs have been isolated (7, 8, 9, 10), and one such Ab, 4D5 or Herceptin, has demonstrated efficacy in the treatment of metastatic breast cancer (11, 12). Although many anti-ErbB-2 Abs inhibit the growth of cancer cells, it is well established that some Abs have no effect on cell growth, while others actively stimulate cancer growth. It has been proposed that this wide spectrum of biological effects is related to the epitope specificity of the Abs and to consequent changes in receptor signaling (13, 14, 15, 16).
Active immunization (vaccination) against ErbB-2 represents an alternative to the use of passive mAb therapy. This strategy is based on data that clearly show that immune tolerance to ErbB-2 is not absolute (17, 18, 19, 20, 21, 22). It is proposed that boosting existing Ab and T cell immune responses or eliciting a de novo immune response will result in a therapeutic benefit. However, the diverse biological effects of murine mAbs (stimulatory and inhibitory) also suggest that an inappropriately induced immune response may have detrimental effects. To better manipulate this Ab response for therapeutic advantage, it is thus crucial to identify epitopes on ErbB-2 that are targeted by stimulatory and inhibitory mAbs.
In this study we have constructed c-erbB2 gene fragment phage display libraries to epitope-map a number of anti-ErbB-2 mAbs with different biological effects on tumor cell growth. Regions that were responsible for opposing effects of mAbs were identified and were used to immunize mice. The B cell epitope region that was recognized by the tumor inhibitory Ab was immunogenic, and the resultant immune response was capable of inhibiting cancer cell growth in vitro. The peptide could serve as a potential lead for vaccine design.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Escherichia coli strains MC1061 and K91Kan, the phage display vector fUSE5, and random peptide libraries (X6, X15, and CX5C) were gifts from Prof. George Smith (University of Missouri, Columbia, MO). The GST gene fusion system was purchased from Amersham Pharmacia Biotech (Castle Hill, Australia).
The anti-ErbB-2 ECD mAbs used in this study were L26, L87, N24, and N29, (Neomarkers, Union City, CA); N12 and N28 (gift from Prof. Y. Yarden, Weizmann Institute of Science, Rehovot, Israel); 9G6 (Santa Cruz Biotechnology, Santa Cruz, CA); and 4D5 (gift from W. Lee, Genentech, South San Francisco, CA). N12 and N28 were provided as ascites fluid and were purified by protein A affinity column (Zymed, San Francisco, CA). Biotinylated N12 used for competitive assay was prepared using EZ-link sulfo-NHS-LC-Biotin (Pierce, Rockford, IL).
The human breast cancer cell lines BT474, SK-BR-3, T47D, and MDA-MB-231 (American Type Culture Collection, Manassas, VA) were cultured in RPMI 1640 medium (Trace, Castle Hill, Australia) supplemented with 10% FCS (Life Technologies, Gaithersburg, MD). Heregulin was a gift from Rodney Fiddes (Garvan Institute of Medical Research, Sydney, Australia).
Construction of c-erbB2 gene fragment libraries and affinity selection
The c-erbB2 gene fragment libraries were constructed in the phage vector fUSE5 following Smith’s (23) and Peterson et al.’s (24) protocols with modifications. In short, the c-erbB2 ECD DNA was excised from the c-erbB2/CMVFLAG vector (25) with HindIII and BspEI and digested with 0.5 U/ml of DNase I. c-erbB2 gene fragments between 100 and 300 bp were purified, end-repaired using T4 DNA polymerase, and blunt end-ligated to the phosphorylated linkers, either FUSP or FUSC, which allowed the peptide to be displayed in a linear or a cyclic form, respectively (24). Linker-ligation-PCR was used to specifically amplify gene fragments containing linkers on both ends (26). The primers used were 5'-ATATCCAGACGCTGGCGGTG-3' and 5'-ATATCCAGCAGCTGGCGGTG-3' for FUSP linker-ligated fragments and 5'-ATATCCAGACGCTGGCTGC-3' and 5'-ATATCCAGCAGCTGGACCGC-3' for FUSC linker-ligated fragments. The PCR-amplified fragments were gel-purified, digested with PflMI enzyme, and ligated to SfiI-digested fUSE5 vector DNA. The ligation mixture was electrotransformed into MC1061, and phage were amplified and titrated (23). A diagnostic PCR was used to determine the number of clones with a gene fragment insert.
For panning, wells of a microtiter plate were coated overnight at 4°C with 100 µl of mAb (10 µg/ml) in PBS and blocked with 0.05% Tween/2% skim milk/PBS. c-erbB2 gene fragment libraries diluted to 1011 transforming units/100 µl in 0.05% Tween/2% skim milk/PBS were added to the wells, and the plate was incubated at 37°C for 1 h. Unbound phage were removed by washing five times in 0.05% Tween/PBS and five times in 0.5% Tween/PBS. Bound phage were eluted with 100 µl of 0.1 M glycine, pH 3.0, for 10 min at room temperature and neutralized with 10 µl of 1 M Tris-HCl, pH 9.5. Eluted phage were used to infect 1 ml of mid-log K91Kan culture and were reamplified for the next round of panning (23, 24). Aliquots of culture were plated onto a Luria Broth/tet20/kan100 plate for colony counting to determine the titer. Three rounds of panning were performed.
Screening for positive clones by phage ELISA and sequence analysis
Single colonies were grown overnight in 1 ml of 2YT/tet20/kan100 with shaking at 37°C. Bacterial cells were spun down, and the supernatant containing phage was added to wells of a microtiter plate coated with 100 µl of an mAb solution (1 µg/ml in PBS) and preblocked with 2% skim milk/PBS. The plate was incubated at 37°C for 1 h and washed three times with 0.05% Tween/PBS. The Ab-phage complexes were detected with mouse anti-M13 HRP conjugates (0.5 µg/ml in 2% skim milk/PBS; Amersham Pharmacia Biotech) followed by incubation with equal parts of tetramethylbenzidine peroxidase substrate and peroxidase solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD). The reaction was stopped with 50 µl of 1 M H2SO4, and the plate was was read at 450 nm with a Dynatech MR7000 spectrophotometer. Clones that showed an absorbance >1.5 vs a background reading of 0.1 were considered positive.
Single-stranded phage DNA was prepared from immunopositive clones by standard techniques and sequenced using the fmol DNA cycle sequencing system (Promega, Annadale, Australia).
Synthesis of immobilized oligopeptides and immunodetection
A series of 15-residue peptides overlapping by one amino acid and covering amino acids C531-A586 and T216-C235 of ErbB-2 ECD was synthesized with an ASP222 machine on activated membranes containing a PEG600 amino spacer (Abimed, Langenfeld, Germany) using F-moc amino acid derivatives (27). Nonspecific binding sites were blocked by overnight incubation of the membranes with 2% skim milk/0.2% Tween/TBS (10 mM Tris-HCl (pH 7.6) and 150 mM NaCl) at 4°C, followed by one wash with 0.2% Tween/TBS. The spots were probed with mAb (4 µg/ml) or dilutions of mouse sera (1/100) in 2% skim milk/TBS at room temperature for 2 h. After three washes with 0.2% Tween/TBS for 10 min at room temperature, the spots were detected with a peroxidase-conjugated goat anti-mouse IgG (Dianova, Hamburg, Germany) diluted in 2% skim milk/TBS for 75 min at room temperature. Following three washes with 0.2% Tween/TBS for 10 min at room temperature, the spots were visualized by detection with ECL Western blotting detection reagents (Amersham Pharmacia Biotech).
MTT cell proliferation assay
Tumor cells were plated in 96-well microtiter plates at an optimal density for linear growth over 4 days: 2000 cells/well for SK-BR-3, T47D, and MDA-MB-231; and 8000 cells/well for BT-474. Cells were allowed to adhere overnight at 37°C. Medium alone or medium containing anti-ErbB-2 mAbs or Heregulin (final concentration, 5 µg/ml and 2.5 nM, respectively) was then added to wells in a final volume of 100 µl. All treatments were performed in triplicate. After 4 days of incubation at 37°C, relative cell numbers were measured indirectly using a nonradioactive cell proliferation assay (Promega, Annandale, Australia) by absorbance readings (OD595 nm–OD630 nm) using a Dynatech MR7000 spectrophotometer. The percent change in relative cell number was calculated by using the following formula: (ODtreated cells - ODuntreated cells)/ODuntreated cells x 100%. The experiment was repeated four times for each cell line.
To assess the effect of mouse sera on cell growth, Igs from mouse sera immunized with GST-EP531 or GST were purified using protein A in 5 M NaCl/150 mM Tris-HCl, pH 8.8, and were dialyzed against PBS. An aliquot (5 µl) of the purified IgG was added to wells in a final volume of 100 µl. The effect of the purified IgG on the growth of BT474 breast cancer cells was assessed as described above. Treatments were performed in triplicate. One-way ANOVA with a Bonferroni post test were used to compare the differences between the mAb and polyclonal Ab treatments. p < 0.05 was considered significant.
Preparation of immunogens and immunizations
Peptides EP531 (C531-A586) and EP216 (T216-C235) of ErbB-2 ECD were subcloned into the EcoRI site of the pGEX-2TK vector (Amersham Pharmacia Biotech). Expression and purification of the GST fusion peptide, GST-EP531 and GST-EP216, were performed following the manufacturer’s instructions.
Groups of female BALB/c mice, 6–8 wk old, were immunized i.p. with 100 µl of GST-EP531, GST-EP216, or GST alone (500 µg/ml) emulsified in IFA. Mice were boosted four times with the Ag in PBS every 2 wk. Sera were taken on day 0 (preimmune) and 10 days after the third and fifth immunizations.
Immunoassays
Ab levels in the sera of immunized mice were assayed by ELISA, using the appropriate Ags.
To determine the anti-peptide response, wells of a microtiter plate
were coated overnight with 10 µg/ml phage pIII-displayed peptides
(
1012 phage particles/ml) in 100 µl of PBS.
The wells were blocked with 2% skim milk/PBS and washed three times
with 0.1% Tween/PBS. Serial dilutions of mouse sera in 2% skim
milk/PBS were added to wells and incubated for 1 h at 37°C.
After washing three times, Ab binding was detected using rabbit
anti-mouse peroxidase conjugates (0.5 µg/ml in 2% skim milk/PBS;
Dako, Carpenteria, CA). Wells coated with phage displaying an unrelated
11-aa long peptide were used to determine the background of nonspecific
Ab binding.
To determine the anti-ErbB-2 response, wells of a microtiter plate were coated overnight at 4°C with 5 µg/ml rabbit anti-ErbB2 Abs (Dako), washed four times with 0.1% Tween/PBS, and blocked with 1% BSA/PBS for 6 h at room temperature with gentle shaking. Wells were then coated overnight at 4°C with either 1% BSA/PBS or SK-BR-3 cell lysate, which was prepared by lysing the cells in lysis buffer containing 1% Triton X-100, 10% glycerol, 150 mM NaCl, 50 mM HEPES (pH 7.5), 1.5 mM MgCl2, 1 mM EDTA, 10 mM pyrophosphate, 100 mM NaF, 0.2 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM PMSF. Wells were then washed four times the next day, serial dilutions of mouse sera in 1% BSA/PBS were added, and the plate was incubated for 2 h at room temperature with gentle shaking. Ab binding was detected using rabbit anti-mouse IgG Ab-peroxidase conjugates (Dako).
For each of the ELISAs described above, a standard curve was constructed using serial dilutions of the mAb N12 of known concentration in blocking solution. The serum Ab titer was calculated with reference to this standard curve and was expressed as micrograms per milliliter.
Competitive ELISA
For competitive inhibition assays, mouse sera obtained 10 days after the final boost were selected on the basis of producing anti-peptide as well as anti-ErbB-2 Abs. Serial dilutions of these sera were performed in 2% BSA/PBS with 5 ng/ml biotinylated mAb N12, added to preblocked microtiter plates coated with 10 µg/ml GST-EP531, and incubated for 2 h at 37°C. After washing in 0.1% Tween/PBS, peroxidase-conjugated strepavidin was used to determine Ab binding. Concomitantly, serial dilutions of sera from mice immunized with GST alone were performed in 2% BSA/PBS with 5 ng/ml biotinylated mAb N12 and were used as negative controls for nonspecific protein inhibition. The percentage of inhibition was calculated by using the following formula: (1 - A/B) x 100%, where A is the absorbance produced by positive mouse sera, and B is the absorbance produced by negative control sera.
Flow cytometry
Breast cancer cells SK-BR-3 (5 x 105) were incubated with 10 µl of mouse serum samples at 4°C for 30 min and then washed twice with 200 µl of 1% BSA/PBS. Goat anti-mouse Ig FITC-conjugated Abs were then added, and the samples were incubated for 30 min at 4°C. After washing, the cells were resuspended in 1% BSA/PBS. The flow cytometric analysis was performed using a MoFlo MLS flow cytometer (Cytomation, Fort Collins, CO). The fluorescence intensity of each cell was measured, and the percentage of positivity was established with respect to an isotype control sample using mouse IgG. A forward scatter vs side scatter gate was used to exclude debris and dead cells.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Two c-erbB2 gene fragment libraries of 7 x 106 (ErbB2-FUSP) and 1 x 107 (ErbB2-FUSC) clones were constructed. PCR analysis revealed inserts in 90 and 100% clones of ErbB2-FUSP and ErbB2-FUSC, respectively. The sizes of the inserts ranged from 50 to 150 bp. Because there were three possible reading frames and two possible insertion orientations, only 1 of 18 of the insert sequences produced a productive phage with ErbB-2 peptides correctly displayed on the surface (23). Therefore, the total number of productive clones was estimated to be 4 x 105 for the ErbB2-FUSP library and 6 x 105 for the ErbB2-FUSC library. Titration after overnight growth yielded 1 x 1012 TU for each library.
Panning of these libraries against the mAbs L26, L87, N12, N24, N29, N28, and 4D5 allowed the identification of phage clones that were reactive with N12, N28, and L87. For mAb L87, the percentage of positive clones increased from 33% (20 of 60) after round 2 to 95% (19 of 20) after round 3. All the clones (60 total) analyzed after rounds 2 and 3 for mAb N28 were positive. As for mAb N12, 9% (8 of 86) of clones analyzed after round 3 were reactive.
Sequence analysis revealed that all eight clones reactive to mAb N12
contained a unique 55-aa insert flanked by FUSP linkers. The insert was
mapped to amino acids C531-A586 within the second cysteine-rich
subdomain of ErbB-2 ECD. The epitope was relatively large and contained
eight cysteine, four glycine, and four proline residues. For mAb L87,
sequencing of 39 clones showed the presence of five inserts of
different lengths all flanked by FUSC linkers. Sequence alignment
mapped the epitope to amino acids T216-C235 within the first
cysteine-rich subregion of ErbB-2 ECD. Similarly, three inserts of
different lengths flanked by FUSC linkers were identified from
sequencing 40 clones reactive to mAb N28. The epitope of N28 overlapped
that of L87, namely T216-C235. The two regions, C531-A586 and
T216-C235, were denoted EP531 and EP216, respectively. The specificity
of the phage clones binding to their respective selector Abs is shown
in Fig. 1
.
|
). The epitope is
thus within the region C220-C235. The strong reactivity of L87 to
peptide 5 and the weak reactivity to peptide 6 suggest that D234
represents a critical residue, and L87 recognizes either a long linear
or an 
-helical epitope (28). The results obtained with
the synthetic peptides thus indicate that L87 and N28 do not recognize
the same epitope.
|
Effects of mAbs N12 and N28 on the proliferation of breast cancer cells
The effects of mAb N12 and N28 on the proliferation of a range of
breast cancer cell lines expressing different levels of ErbB-2 were
studied and compared with those of the mAb 4D5 and Heregulin, a ligand
of ErbB-3 and ErbB-4 (29, 30, 31). It was found that N12
inhibited the growth of breast cancer cells at a level comparable to
that of 4D5 (Fig. 3). In particular, the
inhibitory effect of N12 appeared to correlate with the level of ErbB-2
expression. Cell lines expressing a high level of ErbB-2 (e.g., BT474)
were more growth inhibited by N12 than cell lines expressing a low
level of ErbB-2, such as MDA-MB-231. Both N28 and N12 inhibited the
growth of cell line T47D, which expressed only moderate levels of
ErbB-2. However, in contrast to the effect of N12, N28 consistently
stimulated the growth of both BT474 and SK-BR-3 cells. Although both
cell lines expressed high levels of ErbB-2, N28 had a greater
proliferative effect on BT474 than SK-BR-3 cells.
|
Immune response induced by the peptide regions EP531 and EP216
The peptide regions EP531 and EP216 were expressed as a GST fusion
peptide (GST-EP531 and GST-EP216, respectively), and their
immunogenicities were evaluated in BALB/c mice. Five of six mice (83%)
immunized with GST-EP531 showed an Ab response to peptide EP531 as well
as to whole ErbB-2. The other mouse immunized with GST-EP531 showed an
anti-peptide response, but not an anti-ErbB-2 response.
Although variability between mice was observed, the anti-ErbB-2
response was 6- to 7-fold lower than the anti-EP531 response
(Fig. 4). Both anti-EP531 and
anti-ErbB-2 responses could be detected after the third
immunization, and the responses increased significantly after the fifth
boost (Fig. 4). The induced response was epitope region EP531 specific
and did not cross-react with EP216. No anti-peptide or
anti-ErbB-2 response was observed for mice immunized with GST-EP216
or GST alone. Flow cytometric analysis showed that the sera of mice
immunized with GST-EP531 that had an anti-ErbB-2 response also
reacted with SK-BR-3 breast cancer cells (Fig. 5).
|
|
). As might be
expected with antisera, no precise epitopes could be defined, but
general trends of reactivity showed that sera recognized two separate
groups of peptides located at the N- and C-terminal regions of EP531.
Little or no reactivity was seen with the peptides corresponding to the
central region of EP531. Competitive ELISA (Fig. 7) showed that at a dilution of between
1/20 and 1/80, immunized sera were able to inhibit the binding of mAb
N12 to the peptide EP531, indicating the presence of serum Abs
recognizing the same or a similar determinant as that of the mAb
N12.
|
|
showed that at a concentration of 1.25
µg/ml anti-ErbB-2 Abs (150 µg/ml total IgG), polyclonal IgG
were able to inhibit tumor cell growth up to 85%. The inhibitory
effect of polyclonal IgG was significantly greater than that of N12
(p = 0.014). While the inhibition was also
greater than that observed for 4D5, this difference was not significant
(p = 0.169).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this study we have demonstrated that tumor cell growth can be inhibited by the use of rationally selected ErbB-2 immunogens capable of inducing an anti-ErbB-2 Ab response. The importance of selecting the appropriate immunogen is clearly illustrated by the finding that the epitope specificity of the Ab dictates its biological effect. For instance, we found that mAbs N12 and N28 exert either an inhibitory or a stimulatory effect on tumor cell growth, respectively, by binding to their own specific regions, EP531 and EP216. To avoid possible detrimental effects caused by immunization with the whole ErbB-2 molecule, we chose to use the region EP531, recognized by the tumor inhibitory mAb N12, to ensure the induction of an N12-like inhibitory polyclonal immune response. The resultant site-directed polyclonal Ab response was capable of strongly inhibiting tumor cell proliferation, and the effect was superior to that of 4D5 or N12. While this finding clearly suggests that polyclonal anti-ErbB-2 Abs could produce a more effective anti-tumor response than equivalent doses of a mAb, it should be noted that it may be difficult to directly compare the effects of mAbs with those of Abs containing multiple binding specificities. The efficacy and protective effects of a polyclonal Ab response targeting inhibitory or neutralizing B cell epitopes or regions have been demonstrated repeatedly in the setting of infectious diseases (34, 35, 36). In cancer, few studies have described the induction of epitope-specific B cell immune responses. Our result suggests that this strategy is particularly relevant for ErbB-2, and EP531 is likely to be an important region to target. It is interesting to note that the epitope of 4D5 is reported to be within aa 529–627 of the ECD (37). Lewis-Philips et al. also suggested that anti-ErbB-2 mAbs that bind near the transmembrane region of the ECD have a potent anti-proliferative effect (38). It is thus possible that the region EP531 contains, in addition to the epitope recognized by N12, other B cell epitopes that are important for the inhibitory effects of Abs. In fact, previous studies have shown that certain combinations of anti-ErbB-2 mAbs will have an additive anti-proliferative effect on tumor cell growth (15). When compared with a single-epitope peptide, a peptide that contains multiple epitopes may induce a synergistic, and thus more effective, response.
There are a number of distinct clinical advantages associated with the induction of an anti-ErbB2 inhibitory Ab response. Firstly, it represents an alternative to the injection of large amounts of expensive mAbs. Vaccination using peptidic constructs could also provide a cost-effective means of producing a long term polyclonal immune response. Secondly, as inhibitory anti-ErbB-2 Abs can sensitize tumors to the actions of conventional DNA-damaging drugs (39, 40), inducing such a response may also enhance the efficacy of conventional chemotherapy. Lastly, this vaccination strategy might complement current methods using whole cells (41), ECD (42), DNA (43, 44), or T cell peptide epitopes (45). Although protective immunity against ErbB-2 was demonstrated in these studies, most of them relied on the induction of a CTL response to achieve the desired effect. While CTL are crucial effector cells against cancer, the overwhelmingly high frequency of HLA class I down-regulation in primary breast cancer (up to 88%) (46) and other cancers (47, 48) may limit the potential effectiveness of these vaccines (49, 50).
It is important to note that recent clinical trials have clearly shown that the tolerance against self proteins, such as ErbB-2, can be overcome (51, 52, 53, 54). In the case of ErbB-2, while the use of the whole molecule fails to induce an immune response (55), alternative forms of constructs using ECD (42), a hydrophobized polysaccharide/oncoprotein complex consisting of 147 N-terminal amino acids of ErbB-2 (56), or peptides (54) have successfully been used as immunogens in transgenic mouse models or in humans. If peptide EP531 is immunogenic in humans, it would make an interesting potential vaccine for eliciting a specific inhibitory Ab response in patients.
Clearly, a more thorough understanding of the structure of ErbB-2 as well as its B cell epitopes and the mechanism of action of anti-ErbB-2 Abs will aid in the development of B cell epitope-based immunization strategies. Our study has identified a number of important characteristics related to the epitopes of anti-ErbB-2 Abs. In particular, we found that most Abs recognized large and conformational epitopes. The epitopes of N12 and N28 are conformational. The failure to map the other four mAbs also suggests that the epitopes may consist of carbohydrate residues or amino acid residues that are far apart (>100 aa). Indeed, the mAb 4D5 was reported to recognize a carbohydrate epitope (7). Our observation is in agreement with that of Orlandi et al. (57), who defined a linear subregion of a large conformational epitope of an anti-ErbB-2 mAb using random peptide libraries. In this regard, gene fragment libraries, by displaying on the surface of phage a collection of ErbB-2 peptides of different sizes (up to 100 aa) in their native structural context (58), were shown to be superior to synthetic peptides and random peptide libraries for identifying large and conformational epitope regions. The fine epitope mapping of anti-ErbB-2 Abs will be greatly facilitated once the three-dimensional structure of ErbB-2 is available.
The mechanism by which two Abs with different epitope specificities for ErbB-2 can mediate directly opposing effects remains unknown. The ECD of ErbB-2 plays several important roles in ErbB-2-mediated signaling. Although there is probably no direct ligand for ErbB-2, the ECD of ErbB-2 contains low affinity binding sites for Heregulin and other EGF-like ligands (59), and it is sufficient for mediating heterodimerization with other ErbB receptors (60). These observations suggest the Abs may exert their effects by mimicking or blocking ligand binding or by interfering with heterodimer formation. Alternatively, as bivalency has been reported to be necessary for the action of some anti-ErbB-2 Abs (9), it is possible that they may act by altering the signaling properties of the ErbB-2 homodimer. A recent report showed that the relative geometry of ErbB-2 receptors within the dimer is an important determinant of its signaling properties, and there is a particular ErbB-2 dimer interface that is responsible for its transforming activity (61). It is possible that N12 and N28 may favor the formation of an inactive and active dimer conformation, which results in negative and positive signaling, respectively. Indeed, N28 is reported to induce strong ErbB-2 phosphorylation (8). It is also worth noting that all three mAbs mapped to the two cysteine-rich regions. With the extensive disulfide bond formation, the two cysteine-rich regions could represent important domains for dimerization and thus mediate the diverse effects of anti-ErbB-2 Abs.
In conclusion, our study provides direct evidence of the function-epitope relationship of anti-ErbB-2 Abs and thus emphasizes the need to induce tumor inhibitory Ab responses. The use of a peptide region that contains multiple inhibitory B cell epitopes is likely to be superior to the use of a single epitope immunogen. The use of large peptide vaccines may overcome the tolerance associated with use of the whole ErbB2 molecule, allowing the production of an anti-tumor polyclonal humoral immune response. Further information about the structural properties of ErbB-2 and the mechanism of action of truly protective Abs will no doubt further facilitate the design of effective vaccines against this important receptor.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Prof. Robyn Ward, Department of Medical Oncology, St. Vincent’s Hospital, Darlinghurst, New South Wales 2010, Australia.
3 Abbreviations used in this paper: EGFR, epidermal growth factor receptor; ECD, extracellular domain.
Received for publication October 10, 2000. Accepted for publication February 7, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis PNAS, March 3, 2009; 106(9): 3294 - 3299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu J. Immunol., June 1, 2007; 178(11): 7120 - 7131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Riemer, H. Kurz, M. Klinger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti-Epidermal Growth Factor Receptor Antibodies J Natl Cancer Inst, November 16, 2005; 97(22): 1663 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jiang, W. Liu, H. Qu, L. Meng, S. Song, T. Ouyang, and C. Shou A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2 J. Biol. Chem., February 11, 2005; 280(6): 4656 - 4662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wagner, C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro J. Immunol., January 15, 2005; 174(2): 976 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu J. Immunol., July 1, 2004; 173(1): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Itoh, K. Inoue, T. Tezuka, H. Tada, Y. Hashimoto, T. Masuko, and T. Suzuki Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System J. Biochem., February 1, 2003; 133(2): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, J. Agha, J. J. Roman, L. Hutchins, S. Pecorelli, T. O'Brien, et al. Overexpression of HER-2/Neu in Uterine Serous Papillary Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
